148 related articles for article (PubMed ID: 34466376)
1. Use of FVB Myc-CaP cells as an immune competent, androgen receptor positive, mouse model of prostate cancer bone metastasis.
Wang Y; Herroon MK; Zielske SP; Ellis L; Podgorski I; Taichman RS; Cackowski FC
J Bone Oncol; 2021 Oct; 30():100386. PubMed ID: 34466376
[TBL] [Abstract][Full Text] [Related]
2. Development of a castrate resistant transplant tumor model of prostate cancer.
Ellis L; Lehet K; Ramakrishnan S; Adelaiye R; Pili R
Prostate; 2012 May; 72(6):587-91. PubMed ID: 21796655
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment.
Xu P; Yang JC; Chen B; Nip C; Van Dyke JE; Zhang X; Chen HW; Evans CP; Murphy WJ; Liu C
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37147019
[TBL] [Abstract][Full Text] [Related]
4. A mouse model of prostate cancer bone metastasis in a syngeneic immunocompetent host.
Simons BW; Kothari V; Benzon B; Ghabili K; Hughes R; Zarif JC; Ross AE; Hurley PJ; Schaeffer EM
Oncotarget; 2019 Dec; 10(64):6845-6854. PubMed ID: 31839878
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity.
Nordstrand A; Bovinder Ylitalo E; Thysell E; Jernberg E; Crnalic S; Widmark A; Bergh A; Lerner UH; Wikström P
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670000
[TBL] [Abstract][Full Text] [Related]
7. A hemi-spleen injection model of liver metastasis for prostate cancer.
Simons BW; Dalrymple S; Rosen M; Zheng L; Brennen WN
Prostate; 2020 Oct; 80(14):1263-1269. PubMed ID: 32761950
[TBL] [Abstract][Full Text] [Related]
8. Animal models of bone metastasis.
Rosol TJ; Tannehill-Gregg SH; LeRoy BE; Mandl S; Contag CH
Cancer; 2003 Feb; 97(3 Suppl):748-57. PubMed ID: 12548572
[TBL] [Abstract][Full Text] [Related]
9. Targeting the BMP Pathway in Prostate Cancer Induced Bone Disease.
Straign DM; Ihle CL; Provera MD; Owens P
Front Endocrinol (Lausanne); 2021; 12():769316. PubMed ID: 34956082
[TBL] [Abstract][Full Text] [Related]
10. A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions.
Raheem O; Kulidjian AA; Wu C; Jeong YB; Yamaguchi T; Smith KM; Goff D; Leu H; Morris SR; Cacalano NA; Masuda K; Jamieson CH; Kane CJ; Jamieson CA
J Transl Med; 2011 Oct; 9():185. PubMed ID: 22035283
[TBL] [Abstract][Full Text] [Related]
11. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.
Nemeth JA; Harb JF; Barroso U; He Z; Grignon DJ; Cher ML
Cancer Res; 1999 Apr; 59(8):1987-93. PubMed ID: 10213511
[TBL] [Abstract][Full Text] [Related]
12. Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells.
Corey E; Quinn JE; Bladou F; Brown LG; Roudier MP; Brown JM; Buhler KR; Vessella RL
Prostate; 2002 Jun; 52(1):20-33. PubMed ID: 11992617
[TBL] [Abstract][Full Text] [Related]
13. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone.
Zhang J; Dai J; Qi Y; Lin DL; Smith P; Strayhorn C; Mizokami A; Fu Z; Westman J; Keller ET
J Clin Invest; 2001 May; 107(10):1235-44. PubMed ID: 11375413
[TBL] [Abstract][Full Text] [Related]
14. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo.
Sun YX; Schneider A; Jung Y; Wang J; Dai J; Wang J; Cook K; Osman NI; Koh-Paige AJ; Shim H; Pienta KJ; Keller ET; McCauley LK; Taichman RS
J Bone Miner Res; 2005 Feb; 20(2):318-29. PubMed ID: 15647826
[TBL] [Abstract][Full Text] [Related]
15. Metformin targets c-MYC oncogene to prevent prostate cancer.
Akinyeke T; Matsumura S; Wang X; Wu Y; Schalfer ED; Saxena A; Yan W; Logan SK; Li X
Carcinogenesis; 2013 Dec; 34(12):2823-32. PubMed ID: 24130167
[TBL] [Abstract][Full Text] [Related]
16. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines.
Wu TT; Sikes RA; Cui Q; Thalmann GN; Kao C; Murphy CF; Yang H; Zhau HE; Balian G; Chung LW
Int J Cancer; 1998 Sep; 77(6):887-94. PubMed ID: 9714059
[TBL] [Abstract][Full Text] [Related]
17. Characterization of C4-2 prostate cancer bone metastases and their response to castration.
Pfitzenmaier J; Quinn JE; Odman AM; Zhang J; Keller ET; Vessella RL; Corey E
J Bone Miner Res; 2003 Oct; 18(10):1882-8. PubMed ID: 14584899
[TBL] [Abstract][Full Text] [Related]
18. Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases.
Thudi NK; Martin CK; Murahari S; Shu ST; Lanigan LG; Werbeck JL; Keller ET; McCauley LK; Pinzone JJ; Rosol TJ
Prostate; 2011 May; 71(6):615-25. PubMed ID: 20957670
[TBL] [Abstract][Full Text] [Related]
19. A new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer.
Fradet A; Sorel H; Depalle B; Serre CM; Farlay D; Turtoi A; Bellahcene A; Follet H; Castronovo V; Clézardin P; Bonnelye E
PLoS One; 2013; 8(9):e75092. PubMed ID: 24069383
[TBL] [Abstract][Full Text] [Related]
20. Intra-tibial injection of human prostate cancer cell line CWR22 elicits osteoblastic response in immunodeficient rats.
Andersen C; Bagi CM; Adams SW
J Musculoskelet Neuronal Interact; 2003 Jun; 3(2):148-55. PubMed ID: 15758355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
